Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Read more here.

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Tempus AI Inc (TEM) reports impressive revenue growth, strategic acquisitions, and extended partnerships, setting the stage for a promising 2025.

All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Plus, Nancy Pelosi ...